December 12, 2019
December 12, 2019 – The U.S. FDA has approved Vyondys 53TM (golodirsen) injection, manufactured by Sarepta Pharmaceuticals, to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene amenable to exon 53 skipping. Approximately 8% of DMD patients are eligible